

Ref. No: 2213

Date: 9th December 2025

Subject: New Patients in Gastroenterology

REQUEST

How many new patients were treated by the Trust's Gastroenterology Department in the latest 3 month period of July, August and September (or the latest 3 months available) with the treatments I have provided below?

If you are able to, could you please provide the split of new patients who received their treatment for Crohn's disease and Ulcerative colitis? I have provided a table below. Some treatments can only be used for one condition, which I have blocked out.

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st July 2025, they are not classed as a new patient for the purposes of this question

RESPONSE

	Total		
	Gastroenterology	Crohn's	Ulcerative
	Department	Disease	Colitis
Adalimumab [Humira]	0		
Adalimumab [All Biosimilar]	<5	<5	
Etrasimod	0		
Filgotinib	0		
Golimumab	0		
Infliximab [Remicade]	0		
Infliximab [All Biosimilar]	11	<5	6
Mirikizumab	0		
Ozanimod	0		
Risankizumab	<5	<5	
Tofacitinib	0		
Upadacitinib	<5		<5
Ustekinumab [Stelara]	0		
Ustekinumab [All Biosimilar]	<5	<5	
Vedolizumab	<5	<5	<5